Panel Discussion: Adopting Human-Centric Alternative Models to Navigate the Global Shift Away from NHP Studies and De-Risk Immuno-Oncology Development
- Debating the reality on the ground for biotechs still being pushed for NHP data and managing the gap between progressive policy and conservative reviewer feedback
- Discussing perspectives from the EU, US and Asia around the strategic burden of conducting redundant animal studies to satisfy geographically distinct regulation
- Exploring how smaller biotechs ca balance high cost of NHP studies against the need for convincing data to secure funding, even when alternative models might gain FDA approval